<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01557868</url>
  </required_header>
  <id_info>
    <org_study_id>AOSSM 51H</org_study_id>
    <nct_id>NCT01557868</nct_id>
  </id_info>
  <brief_title>Prediction of Response to Intra-articular Injections of Hyaluronic Acid for Knee Osteoarthritis</brief_title>
  <official_title>Prediction of Response to Intra-articular Injections of Hyaluronic Acid for Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Orthopaedic Society for Sports Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Naval Medical Center, Portsmouth</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>American Orthopaedic Society for Sports Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the investigators can develop a computer
      algorithm to predict which individual patients will respond to injections of hyaluronic acid
      (HA) products for knee osteoarthritis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Osteoarthritis (OA) of the knee is a debilitating condition that affects an
      estimated 21 million Americans. This number is expected to rise steadily as the population
      ages. The medical expenditures associated with arthritis and other rheumatic conditions in
      the United States have increased from $50 billion in 1997 to $86 billion in 2003. In 2003,
      almost 420,000 total knee replacements were performed, primarily for arthritis. Injections of
      hyaluronic acid (HA) have been shown to provide symptom relief for many OA patients who have
      failed to respond to conservative interventions. Many other patients, however, experience
      only slight or no improvement. The results from this study will allow physicians to identify
      whether a patient is likely or not likely to respond well to HA therapy leading to improved
      treatment success rates.

      Goals This study has two related goals: 1) to identify patient and treatment factors that
      predict response to intra-articular injections of hyaluronic acid for knee osteoarthritis
      using multivariable analysis and 2) develop mathematical and statistical models that will
      predict individual patient response to HA for knee OA.

      It is anticipated that the investigators will develop computer software in this study that
      can support clinical decision making related to viscosupplementation in the treatment of knee
      OA. If this project yields successful patient predictive models, physicians who are
      considering a trial of HA for a patient will have some empirical basis for treatment
      selection. Eventually a physician would be able to assess a relatively small number of
      variables for a patient and then be provided with predictions regarding treatment response.

      **Please note that the study site at the Naval Medical Center in Portsmouth, Virginia can
      only enroll patients who are eligible to be treated at a military facility.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain Scale</measure>
    <time_frame>Baseline and at 6 month follow-up</time_frame>
    <description>The KOOS is 42-item patient-report questionnaire that assesses symptoms and problems associated with knee injury and osteoarthritis. It yields scores for five scales including Pain, Other Symptoms, Function in Daily Living, Function in Sport/Recreation, and Knee-Related Quality of Life. We used only the Pain scale which has a range of 0 to 100 where 100 represents the &quot;best&quot; score, i.e., no pain. We reported differences in baseline Pain scale score from Pain scale score at 6 months so these scores could theoretically range from -100 (moving from no pain to maximum pain) to 100 (moving from maximum pain to no pain). Positive change scores represent improvement from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) at 6 Months</measure>
    <time_frame>Assessments were at baseline to 6 month follow-up</time_frame>
    <description>The VAS is a patient-reported assessment of knee pain. Patients mark on a line (0-100mm) their current level of knee pain while moving where 0 represent no pain and 100 represents maximum pain. We report changes in VAS pain rating between baseline and 6 month follow-up. Therefore scores can theoretically range from -100 (moving from maximum pain to no pain) to 100 (moving from no pain to maximum pain). Negative change scores represent decreases in perceived pain or improvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Synvisc (hylan G-F 20)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Euflexxa (1% sodium hyaluronate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hylan G-F 20</intervention_name>
    <description>Three 2 cc injections at weekly intervals</description>
    <arm_group_label>Synvisc (hylan G-F 20)</arm_group_label>
    <other_name>Synvisc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>1% sodium hyaluronate</intervention_name>
    <description>Three 2 cc injections at weekly intervals</description>
    <arm_group_label>Euflexxa (1% sodium hyaluronate)</arm_group_label>
    <other_name>Euflexxa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic knee osteoarthritis presenting to physician's office

          -  Radiographic evidence of knee osteoarthritis

          -  Age 18 years or older

          -  Failed minimum of 3 months of non-operative treatment, including, but not limited to,
             Tylenol, anti-inflammatory medication, cortisone injection, physical therapy, bracing,
             and/or heel wedge

          -  Symptoms for at least 3 months

        Exclusion Criteria:

          -  Associated ligamentous instability

          -  History of deep knee infection

          -  Candidate for total knee arthroplasty or arthroscopy

          -  Peripheral neuropathy.

          -  X-rays that are completely negative and only MRI evidence or arthroscopic evidence
             (from previous arthroscopy) of OA.

          -  Prior HA injections at any point in the past

          -  Chondrocalcinosis

          -  Patients with precautions or contraindications for viscosupplementation use

          -  Cortisone injection within past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Marx, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital for Special Surgery, New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marlene DeMaio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>United States Naval Medical Center, Portsmouth</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Naval Medical Center Portsmouth (this site can only enroll patients who are eligible to be treated at a military facility)</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23708-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.niams.nih.gov/Health_Info/Osteoarthritis/default.asp</url>
    <description>Information on Osteoarthritis from the National Institutes of Health</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/16625635</url>
    <description>Cochrane Review Article Abstract on Viscosupplementation for Knee Osteoarthritis</description>
  </link>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2012</study_first_submitted>
  <study_first_submitted_qc>March 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2012</study_first_posted>
  <results_first_submitted>January 7, 2014</results_first_submitted>
  <results_first_submitted_qc>February 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 2, 2014</results_first_posted>
  <last_update_submitted>February 19, 2014</last_update_submitted>
  <last_update_submitted_qc>February 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
    <mesh_term>Hylan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Synvisc (Hylan G-F 20)</title>
          <description>hylan G-F 20: Three 2 cc injections at weekly intervals</description>
        </group>
        <group group_id="P2">
          <title>Euflexxa (1% Sodium Hyaluronate)</title>
          <description>1% sodium hyaluronate: Three 2 cc injections at weekly intervals</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Synvisc (Hylan G-F 20)</title>
          <description>hylan G-F 20: Three 2 cc injections at weekly intervals</description>
        </group>
        <group group_id="B2">
          <title>Euflexxa (1% Sodium Hyaluronate)</title>
          <description>1% sodium hyaluronate: Three 2 cc injections at weekly intervals</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="95"/>
            <count group_id="B3" value="198"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.5" spread="9.6"/>
                    <measurement group_id="B2" value="43.3" spread="10.4"/>
                    <measurement group_id="B3" value="45.0" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain Scale</title>
        <description>The KOOS is 42-item patient-report questionnaire that assesses symptoms and problems associated with knee injury and osteoarthritis. It yields scores for five scales including Pain, Other Symptoms, Function in Daily Living, Function in Sport/Recreation, and Knee-Related Quality of Life. We used only the Pain scale which has a range of 0 to 100 where 100 represents the &quot;best&quot; score, i.e., no pain. We reported differences in baseline Pain scale score from Pain scale score at 6 months so these scores could theoretically range from -100 (moving from no pain to maximum pain) to 100 (moving from maximum pain to no pain). Positive change scores represent improvement from baseline.</description>
        <time_frame>Baseline and at 6 month follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Synvisc (Hylan G-F 20)</title>
            <description>hylan G-F 20: Three 2 cc injections at weekly intervals</description>
          </group>
          <group group_id="O2">
            <title>Euflexxa (1% Sodium Hyaluronate)</title>
            <description>1% sodium hyaluronate: Three 2 cc injections at weekly intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain Scale</title>
          <description>The KOOS is 42-item patient-report questionnaire that assesses symptoms and problems associated with knee injury and osteoarthritis. It yields scores for five scales including Pain, Other Symptoms, Function in Daily Living, Function in Sport/Recreation, and Knee-Related Quality of Life. We used only the Pain scale which has a range of 0 to 100 where 100 represents the &quot;best&quot; score, i.e., no pain. We reported differences in baseline Pain scale score from Pain scale score at 6 months so these scores could theoretically range from -100 (moving from no pain to maximum pain) to 100 (moving from maximum pain to no pain). Positive change scores represent improvement from baseline.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="18.9"/>
                    <measurement group_id="O2" value="9.8" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analogue Scale (VAS) at 6 Months</title>
        <description>The VAS is a patient-reported assessment of knee pain. Patients mark on a line (0-100mm) their current level of knee pain while moving where 0 represent no pain and 100 represents maximum pain. We report changes in VAS pain rating between baseline and 6 month follow-up. Therefore scores can theoretically range from -100 (moving from maximum pain to no pain) to 100 (moving from no pain to maximum pain). Negative change scores represent decreases in perceived pain or improvement.</description>
        <time_frame>Assessments were at baseline to 6 month follow-up</time_frame>
        <population>The discrepancy between the number of subjects included in this analysis (140) and the number of subjects reported completing the study (141) is due to a missing values for one subject for this variable.</population>
        <group_list>
          <group group_id="O1">
            <title>Synvisc (Hylan G-F 20)</title>
            <description>hylan G-F 20: Three 2 cc injections at weekly intervals</description>
          </group>
          <group group_id="O2">
            <title>Euflexxa (1% Sodium Hyaluronate)</title>
            <description>1% sodium hyaluronate: Three 2 cc injections at weekly intervals</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale (VAS) at 6 Months</title>
          <description>The VAS is a patient-reported assessment of knee pain. Patients mark on a line (0-100mm) their current level of knee pain while moving where 0 represent no pain and 100 represents maximum pain. We report changes in VAS pain rating between baseline and 6 month follow-up. Therefore scores can theoretically range from -100 (moving from maximum pain to no pain) to 100 (moving from no pain to maximum pain). Negative change scores represent decreases in perceived pain or improvement.</description>
          <population>The discrepancy between the number of subjects included in this analysis (140) and the number of subjects reported completing the study (141) is due to a missing values for one subject for this variable.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.7" spread="28.4"/>
                    <measurement group_id="O2" value="-10.7" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Synvisc (Hylan G-F 20)</title>
          <description>hylan G-F 20: Three 2 cc injections at weekly intervals</description>
        </group>
        <group group_id="E2">
          <title>Euflexxa (1% Sodium Hyaluronate)</title>
          <description>1% sodium hyaluronate: Three 2 cc injections at weekly intervals</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Knee Effusion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Barton Mann</name_or_title>
      <organization>American Orthopaedic Society for Sports Medicine</organization>
      <phone>847-292-4900</phone>
      <email>bart@aossm.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

